Echo IQ Limited Expands AI Capabilities Through Exclusive Cardiovascular Data Agreement
Echo IQ Limited (ASX: EIQ) has signed an exclusive agreement with Advara HeartCare that will provide access to a substantial repository of de-identified cardiovascular imaging data to support the development of advanced artificial intelligence solutions. The partnership is expected to deliver between 500,000 and 1,000,000 echocardiography studies, together with associated clinical information, enabling the company to enhance algorithm training, product validation and future technology development. This new data resource complements Echo IQ's existing clinical databases, creating a broader foundation for improving cardiovascular diagnostic software and accelerating innovation. The arrangement also strengthens the company's ability to develop future products while reinforcing its intellectual property position through exclusive access to the dataset. Subject to regulatory and ethics approvals, the agreement has an initial term of three years with an extension option. The collaboration represents a significant strategic step in expanding Echo IQ's AI platform and supporting long-term growth in cardiovascular healthcare technology.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Echo IQ Limited Expands AI Capabilities Through Exclusive Cardiovascular Data Agreement
Echo IQ Limited (ASX: EIQ) has signed an exclusive agreement with Advara HeartCare that will provide access to a substantial repository of de-identified cardiovascular imaging data to support the development of advanced artificial intelligence solutions. The partnership is expected to deliver between 500,000 and 1,000,000 echocardiography studies, together with associated clinical information, enabling the company to enhance algorithm training, product validation and future technology development. This new data resource complements Echo IQ's existing clinical databases, creating a broader foundation for improving cardiovascular diagnostic software and accelerating innovation. The arrangement also strengthens the company's ability to develop future products while reinforcing its intellectual property position through exclusive access to the dataset. Subject to regulatory and ethics approvals, the agreement has an initial term of three years with an extension option. The collaboration represents a significant strategic step in expanding Echo IQ's AI platform and supporting long-term growth in cardiovascular healthcare technology.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au